J Gartrell1, J C Panetta2, S D Baker3, Y L Chen4, D S Hawkins5, A Ostrenga6, T J Scharschmidt7, S L Spunt8, D Wang9, A R Weiss10. 1. Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA. jessica.gartrell@stjude.org. 2. Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA. 3. Pharmaceutics and Pharmacology, The Ohio State University, Columbus, OH, USA. 4. Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA. 5. Hematology/Oncology, Seattle Children's Hospital, Seattle, WA, USA. 6. Pharmacy, University of Mississippi Medical Center, Jackson, MS, USA. 7. Orthopedics, The Ohio State University, Columbus, OH, USA. 8. Pediatrics, Stanford University School of Medicine, Stanford, CA, USA. 9. Radiation Oncology, Rush University Medical Center, Chicago, IL, USA. 10. Pediatrics, Maine Medical Center, Portland, ME, USA.
Abstract
PURPOSE: The use of tyrosine kinase inhibitors for the treatment for soft tissue sarcomas is increasing given promising signals of activity in a variety of tumor types. The recently completed study in non-rhabdomyosarcoma soft tissue sarcomas, ARST1321, demonstrated that the addition of pazopanib to neoadjuvant ifosfamide, doxorubicin, and radiation improved the pathological near complete response rate compared with chemoradiotherapy alone. Pharmacokinetic (PK) evaluation of doxorubicin with pazopanib has not been previously reported. As an exploratory aim, doxorubicin PK data were collected during the dose-finding phase of the study in patients receiving chemotherapy and pazopanib to assess the effect of pazopanib on doxorubicin PK parameters. METHODS: Blood samples were collected during cycle 2 (week 4) of chemotherapy at the following time points from doxorubicin administration: predose, 5, 30, and 60 min, and 2, 4, 8, 24 ± 3, and 48 ± 3 h after dosing. The population pharmacokinetic and individual post hoc estimates of doxorubicin and doxorubicinol were determined by nonlinear mixed-effects modeling. RESULTS: There were 52 doxorubicin and doxorubicinol samples from 7 individuals in this study (median age: 17 years; range 14-23). The doxorubicin clearance was 26.9 (16.1, 36.4, and 33.9) L/h/m2 (post hoc median and range) and 25.8 (23.3%) L/h/m2 [population estimate and IIV (CV%)]. The doxorubicinol apparent clearance was 67.5 (18.2, 1701) L/h/m2 (post hoc median and range) and 58.7 (63.7%) L/h/m2 [population estimate and IIV (CV%)]. CONCLUSION: The PK data of seven patients treated on ARST1321 is consistent with previously reported population and post hoc doxorubicin clearance and doxorubicinol apparent clearance estimates, showing that the addition of pazopanib does not significantly alter doxorubicin pharmacokinetics. These data support the safety of administration of pazopanib with doxorubicin-containing chemotherapy.
PURPOSE: The use of tyrosine kinase inhibitors for the treatment for soft tissue sarcomas is increasing given promising signals of activity in a variety of tumor types. The recently completed study in non-rhabdomyosarcoma soft tissue sarcomas, ARST1321, demonstrated that the addition of pazopanib to neoadjuvant ifosfamide, doxorubicin, and radiation improved the pathological near complete response rate compared with chemoradiotherapy alone. Pharmacokinetic (PK) evaluation of doxorubicin with pazopanib has not been previously reported. As an exploratory aim, doxorubicin PK data were collected during the dose-finding phase of the study in patients receiving chemotherapy and pazopanib to assess the effect of pazopanib on doxorubicin PK parameters. METHODS: Blood samples were collected during cycle 2 (week 4) of chemotherapy at the following time points from doxorubicin administration: predose, 5, 30, and 60 min, and 2, 4, 8, 24 ± 3, and 48 ± 3 h after dosing. The population pharmacokinetic and individual post hoc estimates of doxorubicin and doxorubicinol were determined by nonlinear mixed-effects modeling. RESULTS: There were 52 doxorubicin and doxorubicinol samples from 7 individuals in this study (median age: 17 years; range 14-23). The doxorubicin clearance was 26.9 (16.1, 36.4, and 33.9) L/h/m2 (post hoc median and range) and 25.8 (23.3%) L/h/m2 [population estimate and IIV (CV%)]. The doxorubicinol apparent clearance was 67.5 (18.2, 1701) L/h/m2 (post hoc median and range) and 58.7 (63.7%) L/h/m2 [population estimate and IIV (CV%)]. CONCLUSION: The PK data of seven patients treated on ARST1321 is consistent with previously reported population and post hoc doxorubicin clearance and doxorubicinol apparent clearance estimates, showing that the addition of pazopanib does not significantly alter doxorubicin pharmacokinetics. These data support the safety of administration of pazopanib with doxorubicin-containing chemotherapy.
Authors: Angela C Hirbe; Vanessa Eulo; Chang I Moon; Jingqin Luo; Stephanie Myles; Mahesh Seetharam; Jacqui Toeniskoetter; Tammy Kershner; Sasha Haarberg; Mark Agulnik; Varun Monga; Mohammad Milhem; Amanda Parkes; Steven Robinson; Scott Okuno; Steven Attia; Brian A Van Tine Journal: Eur J Cancer Date: 2020-07-23 Impact factor: 9.162
Authors: Swantje Völler; Joachim Boos; Miriam Krischke; Gudrun Würthwein; Nina E Kontny; Alan V Boddy; Georg Hempel Journal: Clin Pharmacokinet Date: 2015-11 Impact factor: 6.447
Authors: Timothy V Waxweiler; Chad G Rusthoven; Michelle S Proper; Carrye R Cost; Nicholas G Cost; Nathan Donaldson; Timothy Garrington; Brian S Greffe; Travis Heare; Margaret E Macy; Arthur K Liu Journal: Int J Radiat Oncol Biol Phys Date: 2015-06-01 Impact factor: 7.038
Authors: Nina E Kontny; Gudrun Würthwein; Boos Joachim; Alan V Boddy; Miriam Krischke; Uwe Fuhr; Patrick A Thompson; Markus Jörger; Jan H M Schellens; Georg Hempel Journal: Cancer Chemother Pharmacol Date: 2013-01-13 Impact factor: 3.333
Authors: Herbert I Hurwitz; Afshin Dowlati; Shermini Saini; Shawna Savage; A Benjamin Suttle; Diana M Gibson; Jeffrey P Hodge; Elmar M Merkle; Lini Pandite Journal: Clin Cancer Res Date: 2009-06-09 Impact factor: 12.531
Authors: Maria Karlgren; Anna Vildhede; Ulf Norinder; Jacek R Wisniewski; Emi Kimoto; Yurong Lai; Ulf Haglund; Per Artursson Journal: J Med Chem Date: 2012-05-15 Impact factor: 7.446
Authors: Sheri L Spunt; Lynn Million; Yueh-Yun Chi; James Anderson; Jing Tian; Emily Hibbitts; Cheryl Coffin; M Beth McCarville; R Lor Randall; David M Parham; Jennifer O Black; Simon C Kao; Andrea Hayes-Jordan; Suzanne Wolden; Fran Laurie; Roseanne Speights; Ellen Kawashima; Stephen X Skapek; William Meyer; Alberto S Pappo; Douglas S Hawkins Journal: Lancet Oncol Date: 2019-11-27 Impact factor: 54.433